AU2020361608A1 - Metabolic profile screening for gestational diabetes - Google Patents

Metabolic profile screening for gestational diabetes Download PDF

Info

Publication number
AU2020361608A1
AU2020361608A1 AU2020361608A AU2020361608A AU2020361608A1 AU 2020361608 A1 AU2020361608 A1 AU 2020361608A1 AU 2020361608 A AU2020361608 A AU 2020361608A AU 2020361608 A AU2020361608 A AU 2020361608A AU 2020361608 A1 AU2020361608 A1 AU 2020361608A1
Authority
AU
Australia
Prior art keywords
subject
diabetes
test sample
markers
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020361608A
Other languages
English (en)
Inventor
Brian J. KOOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2020361608A1 publication Critical patent/AU2020361608A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2020361608A 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes Pending AU2020361608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914294P 2019-10-11 2019-10-11
US62/914,294 2019-10-11
PCT/US2020/055020 WO2021072222A1 (en) 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes

Publications (1)

Publication Number Publication Date
AU2020361608A1 true AU2020361608A1 (en) 2022-04-21

Family

ID=75436783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020361608A Pending AU2020361608A1 (en) 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes

Country Status (8)

Country Link
US (1) US20240085432A1 (https=)
EP (1) EP4022299A4 (https=)
JP (1) JP7607951B2 (https=)
KR (1) KR20220079582A (https=)
CN (1) CN114761794A (https=)
AU (1) AU2020361608A1 (https=)
CA (1) CA3157057A1 (https=)
WO (1) WO2021072222A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114167066B (zh) * 2022-01-24 2022-06-21 杭州凯莱谱精准医疗检测技术有限公司 生物标志物在制备妊娠糖尿病诊断试剂中的用途
CN117187381B (zh) * 2023-11-03 2024-02-13 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
CA2690541A1 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
EP3094968B1 (en) * 2014-01-15 2020-12-09 The Regents of The University of California Metabolic screening for gestational diabetes
JP2019027885A (ja) 2017-07-28 2019-02-21 国立大学法人千葉大学 妊娠糖尿病の発症リスクの診断用バイオマーカー
US20190310269A1 (en) * 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis

Also Published As

Publication number Publication date
EP4022299A4 (en) 2023-03-01
JP2022551656A (ja) 2022-12-12
CN114761794A (zh) 2022-07-15
KR20220079582A (ko) 2022-06-13
EP4022299A1 (en) 2022-07-06
WO2021072222A1 (en) 2021-04-15
US20240085432A1 (en) 2024-03-14
JP7607951B2 (ja) 2025-01-06
CA3157057A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
Koos et al. Early pregnancy metabolites predict gestational diabetes mellitus: implications for fetal programming
Singer et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes
Siew et al. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes
Steubl et al. Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients
AU2010240781B2 (en) Methods for determining maternal health risks
WO2019195638A1 (en) Systems and methods for measuring obesity using metabolome analysis
Anderson et al. Fetal hemoglobin, α1-microglobulin and hemopexin are potential predictive first trimester biomarkers for preeclampsia
Peters et al. Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II
Artunc-Ulkumen et al. Relationship of neutrophil gelatinase-associated lipocalin (NGAL) and procalcitonin levels with the presence and severity of the preeclampsia
Delić et al. Optimal laboratory panel for predicting preeclampsia
Tamblyn et al. Serum and urine vitamin D metabolite analysis in early preeclampsia
Oğlak et al. The reduced serum concentrations of β-arrestin-1 and β-arrestin-2 in pregnancies complicated with gestational diabetes mellitus
Zorba et al. Visfatin serum levels are increased in women with preeclampsia: a case-control study
Elmas et al. Analysis of urine biomarkers for early determination of acute kidney injury in non-septic and non-asphyxiated critically ill preterm neonates
Saglam et al. Diagnostic value of glycemic markers HbA1c, 1, 5-anhydroglucitol and glycated albumin in evaluating gestational diabetes mellitus
JP7607951B2 (ja) 妊娠性糖尿病に関する代謝プロファイルスクリーニング
van Duijl et al. Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry
Huhn et al. The utility of early gestational OGTT and biomarkers for the development of gestational diabetes mellitus: an international prospective multicentre cohort study
Pecks et al. A mass spectrometric multicenter study supports classification of preeclampsia as heterogeneous disorder
Takahashi et al. Early-pregnancy N-terminal pro-brain natriuretic peptide level is inversely associated with hypertensive disorders of pregnancy diagnosed after 35 weeks of gestation
Venkatesan et al. Performance of European prediction models for classification of type 1 and type 2 diabetes in Indians
Wang et al. Dynamic OGTT-derived C-peptide trajectories for metabolic heterogeneity and adverse pregnancy outcomes in gestational diabetes mellitus: a nested case‒control study
Elitok et al. Urinary neutrophil gelatinase–associated lipocalin/hepcidin-25 ratio for early identification of patients at risk for renal replacement therapy after cardiac surgery: a substudy of the BICARBONATE trial
Callinan et al. Early pregnancy glycaemia predicts postpartum diabetes mellitus
Wang et al. Urinary proteomic analysis during pregnancy and its potential application in early prediction of gestational diabetes mellitus and spontaneous abortion